Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

CEO Says Danish Biotech Wants To Soon Raise $100-$150m

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.    

SNIPR BIOME's first candidate will target only E. coli bacteria in the gut • Source: Alamy

More from Clinical Trials

More from R&D